BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 06, 2009
 |  BioCentury  |  Emerging Company Profile

arGEN-X: Bactrian vs. dromedary

Previous efforts to develop camelid antibodies as therapeutics have focused on fragments of single-domain antibodies that have a heavy chain but not a light chain. arGEN-X B.V. believes its conventional camelid antibody discovery technology should yield full-length antibodies that are more suitable for chronic indications than single-domain camelid approaches, and that require less engineering than antibodies discovered using mouse methods.

The company hopes that demonstrating preclinical proof of concept for its Simple Antibody platform in cancer and autoimmune disease will make it an attractive acquisition target.

In the late 1990s, while working on heavy chain-only camelid mAbs, CSO Hans de Haard conducted research that hinted at the potential usefulness of conventional camelid mAbs. But it wasn't until now that de Haard was able to...

Read the full 605 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >